Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Otolaryngology | 44 | 2023 | 698 | 10.340 |
Why?
|
Rhinitis | 65 | 2023 | 753 | 7.770 |
Why?
|
Sinusitis | 70 | 2023 | 997 | 7.720 |
Why?
|
Otorhinolaryngologic Surgical Procedures | 13 | 2020 | 325 | 2.650 |
Why?
|
Endoscopy | 31 | 2023 | 1854 | 2.520 |
Why?
|
Nasal Polyps | 12 | 2023 | 412 | 2.470 |
Why?
|
Internship and Residency | 23 | 2023 | 5946 | 2.280 |
Why?
|
Paranasal Sinus Neoplasms | 10 | 2024 | 243 | 2.160 |
Why?
|
Paranasal Sinus Diseases | 8 | 2020 | 121 | 2.080 |
Why?
|
Turbinates | 8 | 2019 | 66 | 1.820 |
Why?
|
Paranasal Sinuses | 13 | 2023 | 267 | 1.650 |
Why?
|
Equipment and Supplies | 3 | 2019 | 273 | 1.570 |
Why?
|
Device Approval | 3 | 2019 | 164 | 1.540 |
Why?
|
Nasal Obstruction | 6 | 2019 | 162 | 1.510 |
Why?
|
Education, Medical, Graduate | 13 | 2023 | 2419 | 1.410 |
Why?
|
Maxillary Sinus | 4 | 2023 | 172 | 1.400 |
Why?
|
Personnel Selection | 5 | 2023 | 201 | 1.400 |
Why?
|
Chronic Disease | 65 | 2023 | 9351 | 1.250 |
Why?
|
Maxillary Sinusitis | 3 | 2023 | 40 | 1.210 |
Why?
|
Medicare | 8 | 2023 | 6820 | 0.960 |
Why?
|
Epistaxis | 2 | 2017 | 119 | 0.930 |
Why?
|
Nose Neoplasms | 3 | 2023 | 249 | 0.930 |
Why?
|
Efficiency | 5 | 2021 | 479 | 0.930 |
Why?
|
United States Food and Drug Administration | 5 | 2023 | 1673 | 0.890 |
Why?
|
Quality of Life | 33 | 2024 | 13464 | 0.880 |
Why?
|
Enophthalmos | 2 | 2015 | 34 | 0.870 |
Why?
|
Equipment Safety | 3 | 2018 | 250 | 0.830 |
Why?
|
Adrenal Cortex Hormones | 11 | 2021 | 1882 | 0.830 |
Why?
|
General Surgery | 3 | 2023 | 1722 | 0.770 |
Why?
|
Otorhinolaryngologic Diseases | 2 | 2020 | 97 | 0.760 |
Why?
|
Cross-Sectional Studies | 37 | 2023 | 26280 | 0.730 |
Why?
|
Pain, Postoperative | 3 | 2020 | 1768 | 0.710 |
Why?
|
Fees, Medical | 1 | 2021 | 111 | 0.710 |
Why?
|
Hypersensitivity | 4 | 2024 | 1168 | 0.680 |
Why?
|
Emergency Service, Hospital | 10 | 2020 | 7870 | 0.650 |
Why?
|
Analgesics, Opioid | 3 | 2020 | 3836 | 0.640 |
Why?
|
Capital Financing | 1 | 2019 | 58 | 0.630 |
Why?
|
Clinical Competence | 9 | 2023 | 4859 | 0.630 |
Why?
|
Economics, Hospital | 1 | 2021 | 207 | 0.630 |
Why?
|
Health Care Sector | 2 | 2017 | 196 | 0.620 |
Why?
|
Physicians, Women | 3 | 2020 | 516 | 0.610 |
Why?
|
Bibliometrics | 5 | 2021 | 356 | 0.610 |
Why?
|
United States | 40 | 2023 | 72918 | 0.590 |
Why?
|
Esthesioneuroblastoma, Olfactory | 2 | 2023 | 57 | 0.590 |
Why?
|
Humans | 167 | 2024 | 766019 | 0.570 |
Why?
|
Financing, Government | 1 | 2021 | 473 | 0.570 |
Why?
|
Investments | 1 | 2019 | 148 | 0.570 |
Why?
|
Retrospective Studies | 46 | 2024 | 81544 | 0.560 |
Why?
|
Off-Label Use | 1 | 2019 | 185 | 0.560 |
Why?
|
Career Choice | 4 | 2021 | 768 | 0.550 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2020 | 370 | 0.550 |
Why?
|
Neck Injuries | 2 | 2019 | 162 | 0.550 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2020 | 388 | 0.550 |
Why?
|
Career Mobility | 2 | 2018 | 261 | 0.550 |
Why?
|
Adenoidectomy | 1 | 2018 | 171 | 0.540 |
Why?
|
Hemostatic Techniques | 1 | 2017 | 116 | 0.530 |
Why?
|
Papilloma, Inverted | 1 | 2015 | 19 | 0.510 |
Why?
|
Telemedicine | 3 | 2023 | 3108 | 0.500 |
Why?
|
Professional Autonomy | 3 | 2021 | 172 | 0.500 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2020 | 452 | 0.490 |
Why?
|
Faculty, Medical | 3 | 2018 | 1225 | 0.490 |
Why?
|
Nasal Cavity | 4 | 2024 | 309 | 0.490 |
Why?
|
Tonsillectomy | 1 | 2018 | 284 | 0.480 |
Why?
|
Invasive Pulmonary Aspergillosis | 1 | 2014 | 18 | 0.480 |
Why?
|
Male | 105 | 2023 | 363880 | 0.460 |
Why?
|
Maxillary Sinus Neoplasms | 1 | 2014 | 38 | 0.450 |
Why?
|
Educational Measurement | 4 | 2023 | 1259 | 0.440 |
Why?
|
Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2017 | 452 | 0.440 |
Why?
|
Middle Aged | 82 | 2023 | 223035 | 0.430 |
Why?
|
Healthcare Disparities | 2 | 2021 | 3406 | 0.430 |
Why?
|
Severity of Illness Index | 14 | 2021 | 15882 | 0.430 |
Why?
|
Orbital Diseases | 2 | 2015 | 178 | 0.430 |
Why?
|
Pituitary Neoplasms | 1 | 2022 | 1322 | 0.430 |
Why?
|
Skull Fracture, Basilar | 1 | 2012 | 6 | 0.430 |
Why?
|
Female | 102 | 2023 | 396174 | 0.410 |
Why?
|
Professional Competence | 1 | 2016 | 429 | 0.410 |
Why?
|
Drug Prescriptions | 2 | 2020 | 1662 | 0.410 |
Why?
|
Models, Psychological | 1 | 2017 | 823 | 0.410 |
Why?
|
Product Surveillance, Postmarketing | 1 | 2017 | 463 | 0.410 |
Why?
|
Reimbursement Mechanisms | 1 | 2018 | 669 | 0.410 |
Why?
|
Adult | 71 | 2023 | 223110 | 0.400 |
Why?
|
Cerebrospinal Fluid Rhinorrhea | 1 | 2012 | 87 | 0.400 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2021 | 445 | 0.400 |
Why?
|
Carcinoma, Squamous Cell | 4 | 2021 | 4047 | 0.400 |
Why?
|
Budesonide | 3 | 2023 | 162 | 0.400 |
Why?
|
Biological Products | 1 | 2021 | 947 | 0.400 |
Why?
|
Nose | 4 | 2024 | 519 | 0.390 |
Why?
|
Inappropriate ADH Syndrome | 1 | 2012 | 59 | 0.390 |
Why?
|
Orbit | 1 | 2015 | 458 | 0.380 |
Why?
|
Health Care Reform | 1 | 2021 | 1256 | 0.380 |
Why?
|
Income | 1 | 2020 | 1874 | 0.380 |
Why?
|
Models, Educational | 1 | 2014 | 375 | 0.370 |
Why?
|
Skull Base | 2 | 2021 | 293 | 0.370 |
Why?
|
Hospital Costs | 2 | 2019 | 955 | 0.370 |
Why?
|
Sex Factors | 9 | 2021 | 10611 | 0.360 |
Why?
|
Seasons | 2 | 2019 | 1522 | 0.350 |
Why?
|
Chordoma | 1 | 2013 | 343 | 0.350 |
Why?
|
Head and Neck Neoplasms | 4 | 2024 | 2926 | 0.350 |
Why?
|
Aged | 48 | 2023 | 171170 | 0.340 |
Why?
|
Rhinoplasty | 3 | 2019 | 241 | 0.340 |
Why?
|
Craniocerebral Trauma | 1 | 2014 | 493 | 0.340 |
Why?
|
Drug Approval | 1 | 2017 | 820 | 0.330 |
Why?
|
Prescription Drugs | 1 | 2017 | 634 | 0.330 |
Why?
|
Iatrogenic Disease | 1 | 2012 | 551 | 0.320 |
Why?
|
Tomography, X-Ray Computed | 11 | 2021 | 20699 | 0.320 |
Why?
|
Survival Rate | 2 | 2021 | 12822 | 0.310 |
Why?
|
Nose Diseases | 2 | 2020 | 78 | 0.310 |
Why?
|
Patient Acceptance of Health Care | 2 | 2020 | 3229 | 0.310 |
Why?
|
Coronavirus Infections | 3 | 2020 | 3111 | 0.310 |
Why?
|
Pneumonia, Viral | 3 | 2020 | 3233 | 0.300 |
Why?
|
Publishing | 1 | 2015 | 836 | 0.290 |
Why?
|
Prospective Studies | 32 | 2023 | 54804 | 0.290 |
Why?
|
Disease Management | 1 | 2018 | 2530 | 0.290 |
Why?
|
Cystic Fibrosis | 1 | 2017 | 1284 | 0.280 |
Why?
|
Authorship | 2 | 2021 | 289 | 0.280 |
Why?
|
Biomedical Research | 3 | 2021 | 3458 | 0.280 |
Why?
|
Oropharynx | 1 | 2007 | 139 | 0.260 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2015 | 9378 | 0.260 |
Why?
|
Asthma | 9 | 2023 | 6268 | 0.260 |
Why?
|
Anti-Bacterial Agents | 11 | 2020 | 7474 | 0.260 |
Why?
|
Surgery, Computer-Assisted | 2 | 2022 | 996 | 0.260 |
Why?
|
Empathy | 1 | 2011 | 474 | 0.260 |
Why?
|
Papillomavirus Infections | 2 | 2017 | 1637 | 0.260 |
Why?
|
Depression | 7 | 2019 | 8229 | 0.260 |
Why?
|
Dilatation | 2 | 2017 | 311 | 0.250 |
Why?
|
Natural Orifice Endoscopic Surgery | 2 | 2019 | 119 | 0.240 |
Why?
|
Postoperative Complications | 6 | 2018 | 15804 | 0.240 |
Why?
|
Speech, Esophageal | 1 | 2004 | 11 | 0.230 |
Why?
|
Pharynx | 2 | 2023 | 436 | 0.230 |
Why?
|
Pharyngectomy | 1 | 2004 | 45 | 0.230 |
Why?
|
Ear Diseases | 2 | 2017 | 181 | 0.230 |
Why?
|
Dacryocystorhinostomy | 2 | 2016 | 78 | 0.230 |
Why?
|
Needs Assessment | 2 | 2023 | 1140 | 0.220 |
Why?
|
Nasal Lavage | 1 | 2023 | 17 | 0.220 |
Why?
|
Health Status | 1 | 2017 | 4083 | 0.220 |
Why?
|
Interpersonal Relations | 1 | 2011 | 1432 | 0.210 |
Why?
|
Foreign Bodies | 1 | 2007 | 402 | 0.210 |
Why?
|
Carcinoma | 1 | 2014 | 2313 | 0.200 |
Why?
|
Rhinitis, Allergic, Perennial | 2 | 2013 | 57 | 0.200 |
Why?
|
Laryngectomy | 1 | 2004 | 245 | 0.200 |
Why?
|
Rhinitis, Allergic, Seasonal | 2 | 2013 | 101 | 0.200 |
Why?
|
Operating Rooms | 2 | 2021 | 789 | 0.200 |
Why?
|
Toll-Like Receptor 3 | 2 | 2015 | 98 | 0.190 |
Why?
|
Neurosurgical Procedures | 1 | 2012 | 2078 | 0.190 |
Why?
|
Students, Medical | 1 | 2014 | 1961 | 0.190 |
Why?
|
Endoscopes | 1 | 2022 | 169 | 0.180 |
Why?
|
Pulpitis | 1 | 2021 | 28 | 0.180 |
Why?
|
Aerosols | 2 | 2020 | 634 | 0.180 |
Why?
|
Skull Base Neoplasms | 1 | 2024 | 276 | 0.180 |
Why?
|
Nasal Septum | 2 | 2019 | 131 | 0.170 |
Why?
|
Pandemics | 5 | 2023 | 8724 | 0.170 |
Why?
|
Papillomaviridae | 2 | 2017 | 1137 | 0.170 |
Why?
|
Insurance Coverage | 3 | 2021 | 1945 | 0.160 |
Why?
|
Treatment Outcome | 18 | 2024 | 65203 | 0.160 |
Why?
|
Research Support as Topic | 2 | 2021 | 697 | 0.160 |
Why?
|
Physician Executives | 1 | 2020 | 140 | 0.160 |
Why?
|
Intubation, Intratracheal | 1 | 2007 | 1359 | 0.160 |
Why?
|
Young Adult | 15 | 2019 | 59858 | 0.160 |
Why?
|
Nasal Mucosa | 2 | 2015 | 416 | 0.160 |
Why?
|
Vasculitis | 1 | 2023 | 528 | 0.160 |
Why?
|
Job Application | 1 | 2018 | 38 | 0.160 |
Why?
|
Arkansas | 1 | 2018 | 59 | 0.150 |
Why?
|
Periodicals as Topic | 2 | 2020 | 1463 | 0.150 |
Why?
|
Follow-Up Studies | 14 | 2023 | 39233 | 0.150 |
Why?
|
Avoidance Learning | 1 | 2020 | 248 | 0.150 |
Why?
|
Fractures, Closed | 1 | 2019 | 87 | 0.150 |
Why?
|
Mucociliary Clearance | 1 | 2018 | 81 | 0.150 |
Why?
|
Administration, Oral | 4 | 2019 | 4016 | 0.150 |
Why?
|
Asthma, Aspirin-Induced | 1 | 2021 | 204 | 0.150 |
Why?
|
Tooth Diseases | 1 | 2018 | 73 | 0.150 |
Why?
|
Anti-Asthmatic Agents | 2 | 2020 | 572 | 0.150 |
Why?
|
Fractures, Open | 1 | 2019 | 106 | 0.150 |
Why?
|
Activities of Daily Living | 4 | 2020 | 2419 | 0.140 |
Why?
|
Cockroaches | 1 | 2017 | 92 | 0.140 |
Why?
|
Physician-Patient Relations | 1 | 2011 | 3269 | 0.140 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 249 | 0.140 |
Why?
|
Specialties, Surgical | 1 | 2022 | 391 | 0.140 |
Why?
|
Child | 13 | 2021 | 80567 | 0.140 |
Why?
|
Publications | 1 | 2019 | 195 | 0.140 |
Why?
|
Sodium Chloride | 1 | 2019 | 578 | 0.140 |
Why?
|
Incidence | 4 | 2023 | 21509 | 0.140 |
Why?
|
Risk Assessment | 7 | 2020 | 24272 | 0.130 |
Why?
|
Personality | 1 | 2020 | 559 | 0.130 |
Why?
|
After-Hours Care | 1 | 2017 | 102 | 0.130 |
Why?
|
Self Report | 2 | 2018 | 3769 | 0.130 |
Why?
|
Hypertrophy | 1 | 2018 | 562 | 0.130 |
Why?
|
Absenteeism | 1 | 2018 | 247 | 0.130 |
Why?
|
Sick Leave | 1 | 2017 | 105 | 0.130 |
Why?
|
Child, Preschool | 9 | 2019 | 42509 | 0.130 |
Why?
|
Massachusetts | 5 | 2015 | 8882 | 0.130 |
Why?
|
Rheumatic Diseases | 1 | 2023 | 657 | 0.130 |
Why?
|
Logistic Models | 3 | 2021 | 13272 | 0.130 |
Why?
|
Education | 1 | 2018 | 531 | 0.130 |
Why?
|
Curriculum | 2 | 2023 | 3784 | 0.120 |
Why?
|
Smoking | 3 | 2017 | 9077 | 0.120 |
Why?
|
Aged, 80 and over | 11 | 2019 | 59497 | 0.120 |
Why?
|
Vulnerable Populations | 1 | 2021 | 717 | 0.120 |
Why?
|
Nose Deformities, Acquired | 1 | 2015 | 44 | 0.120 |
Why?
|
Cohort Studies | 10 | 2018 | 41677 | 0.120 |
Why?
|
Congresses as Topic | 1 | 2020 | 811 | 0.120 |
Why?
|
Industry | 1 | 2017 | 362 | 0.120 |
Why?
|
Diagnostic Techniques, Otological | 1 | 2015 | 11 | 0.120 |
Why?
|
Meningioma | 1 | 2024 | 1221 | 0.120 |
Why?
|
Antifungal Agents | 2 | 2017 | 769 | 0.120 |
Why?
|
Combined Modality Therapy | 3 | 2019 | 8524 | 0.120 |
Why?
|
Prednisone | 1 | 2019 | 1566 | 0.120 |
Why?
|
Meningeal Neoplasms | 1 | 2024 | 1252 | 0.120 |
Why?
|
Physical Therapy Modalities | 1 | 2018 | 533 | 0.120 |
Why?
|
Comorbidity | 6 | 2020 | 10577 | 0.120 |
Why?
|
Acute Disease | 4 | 2019 | 7237 | 0.120 |
Why?
|
Eye Infections, Fungal | 1 | 2015 | 99 | 0.110 |
Why?
|
Mucormycosis | 1 | 2015 | 104 | 0.110 |
Why?
|
Larynx | 1 | 2019 | 492 | 0.110 |
Why?
|
Peer Review, Research | 1 | 2017 | 342 | 0.110 |
Why?
|
Airway Remodeling | 1 | 2015 | 134 | 0.110 |
Why?
|
Judgment | 1 | 2016 | 270 | 0.110 |
Why?
|
Ambulatory Care Facilities | 1 | 2020 | 937 | 0.110 |
Why?
|
Telephone | 1 | 2017 | 627 | 0.110 |
Why?
|
Prosthesis Implantation | 1 | 2018 | 594 | 0.110 |
Why?
|
Frontal Sinus | 1 | 2013 | 51 | 0.110 |
Why?
|
Activins | 1 | 2015 | 210 | 0.110 |
Why?
|
Problem Solving | 1 | 2016 | 442 | 0.110 |
Why?
|
Consensus | 3 | 2021 | 3200 | 0.110 |
Why?
|
Aspergillosis | 1 | 2015 | 242 | 0.110 |
Why?
|
Lacrimal Duct Obstruction | 1 | 2013 | 53 | 0.110 |
Why?
|
Intubation | 1 | 2013 | 140 | 0.110 |
Why?
|
Neoplasm Staging | 2 | 2021 | 11202 | 0.100 |
Why?
|
Cautery | 1 | 2013 | 73 | 0.100 |
Why?
|
Adolescent | 10 | 2019 | 88808 | 0.100 |
Why?
|
Nasolacrimal Duct | 1 | 2013 | 79 | 0.100 |
Why?
|
Algorithms | 1 | 2013 | 14065 | 0.100 |
Why?
|
Bacterial Infections | 1 | 2021 | 1387 | 0.100 |
Why?
|
Ligation | 1 | 2013 | 446 | 0.100 |
Why?
|
Steroids | 1 | 2017 | 934 | 0.100 |
Why?
|
Organ Culture Techniques | 1 | 2014 | 788 | 0.100 |
Why?
|
Pilot Projects | 2 | 2019 | 8723 | 0.100 |
Why?
|
Hypopharyngeal Neoplasms | 1 | 2012 | 52 | 0.100 |
Why?
|
Catheterization | 1 | 2017 | 1426 | 0.100 |
Why?
|
Societies, Medical | 2 | 2021 | 3955 | 0.090 |
Why?
|
Bandages | 1 | 2013 | 270 | 0.090 |
Why?
|
Odds Ratio | 3 | 2018 | 9655 | 0.090 |
Why?
|
Disease Progression | 6 | 2018 | 13614 | 0.090 |
Why?
|
Multivariate Analysis | 4 | 2020 | 12061 | 0.090 |
Why?
|
Patient Selection | 2 | 2018 | 4249 | 0.090 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2015 | 637 | 0.090 |
Why?
|
Risk Factors | 10 | 2020 | 74837 | 0.090 |
Why?
|
Surgical Flaps | 2 | 2013 | 1677 | 0.090 |
Why?
|
Accreditation | 1 | 2014 | 476 | 0.090 |
Why?
|
Autoimmune Diseases | 1 | 2023 | 2249 | 0.090 |
Why?
|
Clinical Trials as Topic | 2 | 2017 | 8037 | 0.090 |
Why?
|
Health Care Costs | 2 | 2014 | 3240 | 0.090 |
Why?
|
Headache | 1 | 2018 | 1259 | 0.090 |
Why?
|
Ophthalmology | 1 | 2017 | 559 | 0.090 |
Why?
|
Cochlear Implantation | 1 | 2014 | 317 | 0.090 |
Why?
|
Sex Characteristics | 1 | 2021 | 2646 | 0.090 |
Why?
|
Infant | 4 | 2016 | 36424 | 0.090 |
Why?
|
Education, Medical, Continuing | 1 | 2015 | 829 | 0.090 |
Why?
|
Organ Size | 1 | 2015 | 2260 | 0.080 |
Why?
|
Fellowships and Scholarships | 1 | 2018 | 1134 | 0.080 |
Why?
|
Prognosis | 5 | 2019 | 29905 | 0.080 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7840 | 0.080 |
Why?
|
Health Status Indicators | 1 | 2014 | 967 | 0.080 |
Why?
|
Patient Preference | 1 | 2017 | 946 | 0.080 |
Why?
|
Workload | 1 | 2015 | 849 | 0.080 |
Why?
|
Liposarcoma | 1 | 2012 | 288 | 0.080 |
Why?
|
Health Services Needs and Demand | 1 | 2017 | 1404 | 0.080 |
Why?
|
Complex Mixtures | 1 | 2008 | 29 | 0.080 |
Why?
|
Regression Analysis | 1 | 2018 | 6324 | 0.080 |
Why?
|
Cost-Benefit Analysis | 3 | 2016 | 5528 | 0.080 |
Why?
|
Bone Transplantation | 1 | 2013 | 920 | 0.080 |
Why?
|
SEER Program | 1 | 2013 | 1443 | 0.080 |
Why?
|
Emotions | 1 | 2020 | 2758 | 0.080 |
Why?
|
Allergens | 1 | 2016 | 1435 | 0.070 |
Why?
|
Databases, Factual | 3 | 2019 | 8062 | 0.070 |
Why?
|
Disease-Free Survival | 2 | 2019 | 6840 | 0.070 |
Why?
|
Survival Analysis | 3 | 2019 | 10089 | 0.070 |
Why?
|
Chemokine CCL5 | 1 | 2008 | 213 | 0.070 |
Why?
|
Hematoma | 1 | 2013 | 765 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 2 | 2019 | 6506 | 0.070 |
Why?
|
Patient Satisfaction | 4 | 2014 | 3477 | 0.070 |
Why?
|
Analysis of Variance | 1 | 2016 | 6208 | 0.070 |
Why?
|
Risk | 2 | 2017 | 9598 | 0.070 |
Why?
|
Diagnosis, Differential | 3 | 2012 | 12975 | 0.070 |
Why?
|
Administration, Intranasal | 2 | 2019 | 482 | 0.070 |
Why?
|
Educational Status | 1 | 2015 | 2507 | 0.070 |
Why?
|
Biocompatible Materials | 1 | 2016 | 1685 | 0.070 |
Why?
|
Case-Control Studies | 3 | 2021 | 22230 | 0.070 |
Why?
|
Medicaid | 1 | 2021 | 2835 | 0.070 |
Why?
|
Patient Admission | 1 | 2015 | 1364 | 0.070 |
Why?
|
Gastroesophageal Reflux | 1 | 2015 | 834 | 0.070 |
Why?
|
Sensitivity and Specificity | 3 | 2019 | 14644 | 0.070 |
Why?
|
Proportional Hazards Models | 1 | 2021 | 12529 | 0.070 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3604 | 0.060 |
Why?
|
Cadaver | 2 | 2020 | 1362 | 0.060 |
Why?
|
Smoking Cessation | 1 | 2017 | 2082 | 0.060 |
Why?
|
Diagnostic Errors | 1 | 2013 | 1276 | 0.060 |
Why?
|
Predictive Value of Tests | 3 | 2018 | 15403 | 0.060 |
Why?
|
Software | 2 | 2022 | 4463 | 0.060 |
Why?
|
Syndrome | 1 | 2011 | 3270 | 0.060 |
Why?
|
Time Factors | 5 | 2023 | 40100 | 0.060 |
Why?
|
Hospital Mortality | 1 | 2019 | 5339 | 0.060 |
Why?
|
Health Surveys | 1 | 2014 | 4054 | 0.060 |
Why?
|
Attitude | 2 | 2019 | 767 | 0.060 |
Why?
|
Quality Improvement | 1 | 2019 | 3849 | 0.060 |
Why?
|
Biopsy | 2 | 2015 | 6768 | 0.050 |
Why?
|
Perception | 2 | 2020 | 1204 | 0.050 |
Why?
|
Boston | 1 | 2016 | 9335 | 0.050 |
Why?
|
Sex Distribution | 2 | 2020 | 2269 | 0.050 |
Why?
|
Emergency Medical Services | 1 | 2014 | 1937 | 0.050 |
Why?
|
Tobacco Smoke Pollution | 1 | 2008 | 828 | 0.050 |
Why?
|
Linear Models | 3 | 2019 | 5872 | 0.050 |
Why?
|
Jejunum | 1 | 2004 | 474 | 0.050 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4045 | 0.050 |
Why?
|
Morbidity | 2 | 2019 | 1753 | 0.050 |
Why?
|
Stents | 1 | 2013 | 3191 | 0.050 |
Why?
|
Leadership | 2 | 2021 | 1394 | 0.050 |
Why?
|
Viridans Streptococci | 1 | 2021 | 16 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 10380 | 0.050 |
Why?
|
Cells, Cultured | 2 | 2014 | 18965 | 0.050 |
Why?
|
Gastric Mucosa | 1 | 2004 | 602 | 0.050 |
Why?
|
Academic Medical Centers | 3 | 2018 | 2782 | 0.050 |
Why?
|
Research Design | 1 | 2017 | 6205 | 0.050 |
Why?
|
Sneezing | 1 | 2020 | 16 | 0.040 |
Why?
|
Propensity Score | 2 | 2019 | 1973 | 0.040 |
Why?
|
ROC Curve | 2 | 2018 | 3614 | 0.040 |
Why?
|
Governing Board | 1 | 2020 | 50 | 0.040 |
Why?
|
Tracheostomy | 1 | 2004 | 430 | 0.040 |
Why?
|
Drug Implants | 1 | 2020 | 230 | 0.040 |
Why?
|
Nasal Sprays | 1 | 2019 | 27 | 0.040 |
Why?
|
Periapical Abscess | 1 | 2018 | 17 | 0.040 |
Why?
|
Medication Therapy Management | 1 | 2019 | 131 | 0.040 |
Why?
|
Cultural Diversity | 1 | 2022 | 370 | 0.040 |
Why?
|
Absorbable Implants | 1 | 2020 | 333 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2021 | 792 | 0.040 |
Why?
|
Prevalence | 1 | 2014 | 15820 | 0.040 |
Why?
|
Leukotriene Antagonists | 1 | 2017 | 124 | 0.030 |
Why?
|
Faculty | 1 | 2020 | 383 | 0.030 |
Why?
|
Current Procedural Terminology | 1 | 2017 | 101 | 0.030 |
Why?
|
Epithelial Cells | 1 | 2008 | 3684 | 0.030 |
Why?
|
Tooth | 1 | 2018 | 210 | 0.030 |
Why?
|
Medicare Part B | 1 | 2017 | 116 | 0.030 |
Why?
|
Particle Size | 1 | 2020 | 1630 | 0.030 |
Why?
|
Mucorales | 1 | 2015 | 35 | 0.030 |
Why?
|
Aspergillus | 1 | 2015 | 93 | 0.030 |
Why?
|
Bayes Theorem | 1 | 2023 | 2352 | 0.030 |
Why?
|
Factor Analysis, Statistical | 1 | 2017 | 1001 | 0.030 |
Why?
|
Hyperbaric Oxygenation | 1 | 2015 | 167 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 1 | 2019 | 1777 | 0.030 |
Why?
|
Postoperative Period | 1 | 2019 | 1820 | 0.030 |
Why?
|
Opportunistic Infections | 1 | 2016 | 376 | 0.030 |
Why?
|
Private Practice | 1 | 2014 | 154 | 0.030 |
Why?
|
Length of Stay | 2 | 2019 | 6489 | 0.030 |
Why?
|
Debridement | 1 | 2015 | 494 | 0.030 |
Why?
|
Conflict of Interest | 1 | 2017 | 556 | 0.020 |
Why?
|
Mutation | 1 | 2017 | 30210 | 0.020 |
Why?
|
Hospitals, University | 1 | 2014 | 572 | 0.020 |
Why?
|
Radiography | 2 | 2013 | 6943 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2015 | 948 | 0.020 |
Why?
|
Models, Organizational | 1 | 2014 | 548 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2008 | 11906 | 0.020 |
Why?
|
Cost of Illness | 1 | 2020 | 1949 | 0.020 |
Why?
|
Forecasting | 1 | 2019 | 2935 | 0.020 |
Why?
|
Medical Staff, Hospital | 1 | 2014 | 601 | 0.020 |
Why?
|
Triage | 1 | 2017 | 994 | 0.020 |
Why?
|
Phenotype | 2 | 2019 | 16714 | 0.020 |
Why?
|
Aspirin | 1 | 2021 | 3135 | 0.020 |
Why?
|
Program Evaluation | 1 | 2018 | 2501 | 0.020 |
Why?
|
Validation Studies as Topic | 1 | 2010 | 162 | 0.020 |
Why?
|
Health Care Surveys | 1 | 2017 | 2425 | 0.020 |
Why?
|
Costs and Cost Analysis | 1 | 2015 | 1666 | 0.020 |
Why?
|
Chemokine CCL7 | 1 | 2008 | 30 | 0.020 |
Why?
|
Age Distribution | 1 | 2015 | 2865 | 0.020 |
Why?
|
Immunochemistry | 1 | 2008 | 116 | 0.020 |
Why?
|
beta-Defensins | 1 | 2008 | 58 | 0.020 |
Why?
|
Patients | 1 | 2015 | 908 | 0.020 |
Why?
|
Social Class | 1 | 2017 | 2006 | 0.020 |
Why?
|
Cause of Death | 1 | 2019 | 3712 | 0.020 |
Why?
|
Hospitals, Pediatric | 1 | 2017 | 1850 | 0.020 |
Why?
|
Cluster Analysis | 1 | 2015 | 2718 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2014 | 1737 | 0.020 |
Why?
|
Medication Adherence | 1 | 2019 | 2190 | 0.020 |
Why?
|
RNA, Double-Stranded | 1 | 2008 | 292 | 0.020 |
Why?
|
Interferon-beta | 1 | 2008 | 347 | 0.020 |
Why?
|
Recurrence | 1 | 2018 | 8494 | 0.020 |
Why?
|
Interleukin-8 | 1 | 2008 | 699 | 0.020 |
Why?
|
Interferons | 1 | 2008 | 714 | 0.010 |
Why?
|
Data Collection | 1 | 2014 | 3318 | 0.010 |
Why?
|
Interleukins | 1 | 2008 | 789 | 0.010 |
Why?
|
Neurons | 1 | 2023 | 9521 | 0.010 |
Why?
|
Graft Survival | 1 | 2013 | 3904 | 0.010 |
Why?
|
Interleukin-1beta | 1 | 2008 | 1027 | 0.010 |
Why?
|
Pain | 1 | 2017 | 5089 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2018 | 14747 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2008 | 2212 | 0.010 |
Why?
|
Graft Rejection | 1 | 2013 | 4504 | 0.010 |
Why?
|
Computer Simulation | 1 | 2014 | 6254 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20135 | 0.010 |
Why?
|
Pediatrics | 1 | 2014 | 3609 | 0.010 |
Why?
|
Hospitalization | 1 | 2019 | 10804 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2008 | 3227 | 0.010 |
Why?
|
Animals | 2 | 2023 | 168801 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2008 | 4342 | 0.010 |
Why?
|
Mice | 1 | 2023 | 81838 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2015 | 26379 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2008 | 12772 | 0.010 |
Why?
|